Preventing Blood-Retinal Barrier Dysfunction in Diabetes
Author Information
Author(s): Paul Canning, Josephine V. Glenn, Daniel K. Hsu, Fu-Tong Liu, Tom A. Gardiner, Alan W. Stitt
Primary Institution: Queen's University Belfast
Hypothesis
Can advanced glycation end products (AGEs) and galectin-3 (Gal-3) influence blood-retinal barrier dysfunction in diabetes?
Conclusion
Inhibiting AGEs or deleting Gal-3 can prevent blood-retinal barrier dysfunction in diabetic mice.
Supporting Evidence
- Diabetic WT mice showed significant blood-retinal barrier breakdown.
- PM-treated diabetics had normal blood-retinal barrier function.
- Gal-3−/− mice showed significantly less blood-retinal barrier dysfunction than WT mice.
Takeaway
When mice get diabetes, their eyes can get leaky and cause vision problems, but a special treatment can help keep their eyes healthy.
Methodology
Diabetes was induced in mice, and the effects of an AGE inhibitor were assessed on blood-retinal barrier integrity and VEGF expression.
Limitations
The study was conducted in mice, which may not fully replicate human diabetic retinopathy.
Participant Demographics
C57/BL6 wild-type and Gal-3−/− transgenic mice, aged 6-8 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website